Status | Study |
Not yet recruiting |
Study Name: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Condition: Acral Lentiginous Melanoma Mucosal Melanoma Date: 2016-11-23 Interventions: Drug: Nivolumab Other Names: |
Recruiting |
Study Name: Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma Condition: Acral Lentiginous Melanoma Date: 2016-08-07 Interventions: Drug: pembrolizumab pembrolizumab at 200mg IV infusion every 3 weeks |
Not yet recruiting |
Study Name: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma Date: 2011-04-13 Interventions: Drug: nilotinib nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatm |
Terminated |
Study Name: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Condition: Acral Lentiginous Malignant Melanoma Lentigo Maligna Malignant Date: 2010-05-07 Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097 |
Terminated |
Study Name: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Condition: Melanoma Date: 2010-03-23 Interventions: Drug: Dasatinib 100 mg daily. |
Active, not recruiting |
Study Name: Dinaciclib in Treating Patients With Stage IV Melanoma Condition: Acral Lentiginous Melanoma Lentigo Maligna Melanoma Date: 2009-07-10 Interventions: Drug: Dinaciclib Given IV Other Names: |
Completed |
Study Name: Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Condition: Melanoma (Skin) Date: 2008-06-18 Interventions: Drug: dasatinib Other: laboratory biomarke |
Completed |
Study Name: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Condition: Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma Date: 2007-12-18 Interventions: Drug: Sunitinib Other Names: Sutent SU011248 |
Completed |
Study Name: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Condition: Acral Lentiginous Malignant Melanoma Recurrent Melanoma Date: 2007-05-03 Interventions: Drug: imatinib mesylate Given |
Recruiting |
Study Name: Study of Families With Melanoma Condition: Melanoma (Skin) Date: 2007-03-07 Interventions: Genetic: gene expression analysis Genetic: |